Molecular markers of proliferation, DNA repair, and immune infiltration defines high-risk subset of resectable retroperitoneal sarcomas

IF 2.3 4区 医学 Q3 ONCOLOGY Surgical Oncology-Oxford Pub Date : 2024-08-26 DOI:10.1016/j.suronc.2024.102125
Nathan D. Seligson , Yan W. Asmann , Tariq Almerey , Yaquelin Coll Zayas , Mark A. Edgar , Steven Attia , Keith L. Knutson , Sanjay P. Bagaria
{"title":"Molecular markers of proliferation, DNA repair, and immune infiltration defines high-risk subset of resectable retroperitoneal sarcomas","authors":"Nathan D. Seligson ,&nbsp;Yan W. Asmann ,&nbsp;Tariq Almerey ,&nbsp;Yaquelin Coll Zayas ,&nbsp;Mark A. Edgar ,&nbsp;Steven Attia ,&nbsp;Keith L. Knutson ,&nbsp;Sanjay P. Bagaria","doi":"10.1016/j.suronc.2024.102125","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>For retroperitoneal sarcomas (RPS), aggressive surgical resection offers the only chance for a cure; however, 5-year survival remains below 65%. Therefore, there is a critical need to identify drivers of poor clinical outcomes.</p></div><div><h3>Materials and methods</h3><p>To identify biomarkers of tumors likely to recur following curative intent resection, we performed genomic and transcriptomic sequencing for 47 and 34 patients, respectively, with non-metastatic RPS at a single, high-volume sarcoma center.</p></div><div><h3>Results</h3><p>At the DNA level, alterations in <em>TERT</em> were associated with poor disease-free survival (DFS) and overall survival (OS). Increased RNA expression of gene sets related to growth signaling and DNA repair were associated with poor DFS and OS. Infiltration of CD8<sup>+</sup> T-Cells and activated dendritic cells were associated with poor DFS and OS.</p></div><div><h3>Conclusion</h3><p>These findings may help to better identify and treat non-metastatic, high-risk RPS.</p></div>","PeriodicalId":51185,"journal":{"name":"Surgical Oncology-Oxford","volume":null,"pages":null},"PeriodicalIF":2.3000,"publicationDate":"2024-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Surgical Oncology-Oxford","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0960740424000938","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction

For retroperitoneal sarcomas (RPS), aggressive surgical resection offers the only chance for a cure; however, 5-year survival remains below 65%. Therefore, there is a critical need to identify drivers of poor clinical outcomes.

Materials and methods

To identify biomarkers of tumors likely to recur following curative intent resection, we performed genomic and transcriptomic sequencing for 47 and 34 patients, respectively, with non-metastatic RPS at a single, high-volume sarcoma center.

Results

At the DNA level, alterations in TERT were associated with poor disease-free survival (DFS) and overall survival (OS). Increased RNA expression of gene sets related to growth signaling and DNA repair were associated with poor DFS and OS. Infiltration of CD8+ T-Cells and activated dendritic cells were associated with poor DFS and OS.

Conclusion

These findings may help to better identify and treat non-metastatic, high-risk RPS.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
增殖、DNA 修复和免疫浸润的分子标记定义了可切除腹膜后肉瘤的高风险亚群
导言对于腹膜后肉瘤(RPS),积极的手术切除是治愈的唯一机会;然而,5年生存率仍低于65%。为了确定治愈性切除术后可能复发的肿瘤的生物标志物,我们在一个高容量的肉瘤中心分别对47例和34例非转移性RPS患者进行了基因组和转录组测序。与生长信号转导和DNA修复相关的基因组的RNA表达增加与无病生存率和总生存率低有关。CD8+T细胞和活化树突状细胞的浸润与无病生存期和总生存期差有关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Surgical Oncology-Oxford
Surgical Oncology-Oxford 医学-外科
CiteScore
4.50
自引率
0.00%
发文量
169
审稿时长
38 days
期刊介绍: Surgical Oncology is a peer reviewed journal publishing review articles that contribute to the advancement of knowledge in surgical oncology and related fields of interest. Articles represent a spectrum of current technology in oncology research as well as those concerning clinical trials, surgical technique, methods of investigation and patient evaluation. Surgical Oncology publishes comprehensive Reviews that examine individual topics in considerable detail, in addition to editorials and commentaries which focus on selected papers. The journal also publishes special issues which explore topics of interest to surgical oncologists in great detail - outlining recent advancements and providing readers with the most up to date information.
期刊最新文献
Machine learning in cancer prognostication: Limitations and opportunities. Bilobed lateral artery perforator-based flap for partial breast reconstruction - Technique description and results from a ten-year cohort. Individualizing care for patients with gallbladder cancer Natural history of salivary gland secretory carcinoma: A REFCOR study. Tumor necrosis drives prognosis in osteosarcoma: No difference in chemotherapy response and survival between chondroblastic and osteoblastic osteosarcoma
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1